Intra-Cellular Therapies ITCI Stock
Intra-Cellular Therapies Price Chart
Intra-Cellular Therapies ITCI Financial and Trading Overview
| Intra-Cellular Therapies stock price | 65.88 USD |
| Previous Close | 64.4 USD |
| Open | 64.31 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1000 |
| Day's Range | 63.51 - 64.59 USD |
| 52 Week Range | 42.01 - 66.56 USD |
| Volume | 452.17K USD |
| Avg. Volume | 831.14K USD |
| Market Cap | 6.17B USD |
| Beta (5Y Monthly) | 1.126408 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.46 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 76.5 USD |
ITCI Valuation Measures
| Enterprise Value | 5.66B USD |
| Trailing P/E | N/A |
| Forward P/E | -103.661285 |
| PEG Ratio (5 yr expected) | -0.29 |
| Price/Sales (ttm) | 19.84759 |
| Price/Book (mrq) | 9.798749 |
| Enterprise Value/Revenue | 18.213 |
| Enterprise Value/EBITDA | -23.697 |
Trading Information
Intra-Cellular Therapies Stock Price History
| Beta (5Y Monthly) | 1.126408 |
| 52-Week Change | 16.98% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 66.56 USD |
| 52 Week Low | 42.01 USD |
| 50-Day Moving Average | 62.29 USD |
| 200-Day Moving Average | 52.47 USD |
ITCI Share Statistics
| Avg. Volume (3 month) | 831.14K USD |
| Avg. Daily Volume (10-Days) | 676.71K USD |
| Shares Outstanding | 95.93M |
| Float | 93.64M |
| Short Ratio | 4.45 |
| % Held by Insiders | 2.59% |
| % Held by Institutions | 93.95% |
| Shares Short | 3.44M |
| Short % of Float | 4.16% |
| Short % of Shares Outstanding | 3.59% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -73.46% |
| Operating Margin (ttm) | -77.057% |
| Gross Margin | 46.00% |
| EBITDA Margin | -76.85% |
Management Effectiveness
| Return on Assets (ttm) | -18.80% |
| Return on Equity (ttm) | -32.13% |
Income Statement
| Revenue (ttm) | 310.62M USD |
| Revenue Per Share (ttm) | 3.28 USD |
| Quarterly Revenue Growth (yoy) | 172.30% |
| Gross Profit (ttm) | 95.16M USD |
| EBITDA | -238736992 USD |
| Net Income Avi to Common (ttm) | -228190000 USD |
| Diluted EPS (ttm) | -2.4 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 538.71M USD |
| Total Cash Per Share (mrq) | 5.62 USD |
| Total Debt (mrq) | 18.49M USD |
| Total Debt/Equity (mrq) | 2.95 USD |
| Current Ratio (mrq) | 8.872 |
| Book Value Per Share (mrq) | 6.559 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -247403008 USD |
| Levered Free Cash Flow (ttm) | -170029504 USD |
Profile of Intra-Cellular Therapies
| Country | United States |
| State | NY |
| City | New York |
| Address | 430 East 29th Street |
| ZIP | 10016 |
| Phone | 646 440 9333 |
| Website | https://www.intracellulartherapies.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 561 |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Q&A For Intra-Cellular Therapies Stock
What is a current ITCI stock price?
Intra-Cellular Therapies ITCI stock price today per share is 65.88 USD.
How to purchase Intra-Cellular Therapies stock?
You can buy ITCI shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Intra-Cellular Therapies?
The stock symbol or ticker of Intra-Cellular Therapies is ITCI.
Which industry does the Intra-Cellular Therapies company belong to?
The Intra-Cellular Therapies industry is Drug Manufacturers-Specialty & Generic.
How many shares does Intra-Cellular Therapies have in circulation?
The max supply of Intra-Cellular Therapies shares is 96.81M.
What is Intra-Cellular Therapies Price to Earnings Ratio (PE Ratio)?
Intra-Cellular Therapies PE Ratio is now.
What was Intra-Cellular Therapies earnings per share over the trailing 12 months (TTM)?
Intra-Cellular Therapies EPS is -1.46 USD over the trailing 12 months.
Which sector does the Intra-Cellular Therapies company belong to?
The Intra-Cellular Therapies sector is Healthcare.
Intra-Cellular Therapies ITCI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2541.54 USD — |
-1.89
|
— — | 2531.95 USD — | 2572.66 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}